Introduction
A significant percentage of patients with diabetes develop chronic kidney disease (CKD), and diabetes is also a leading cause of end-stage renal disease. 1 More than a quarter of patients who are on dialysis in the UK have diabetes. 2 Diabetic kidney disease is associated with high morbidity and mortality, which are predominantly related to cardiovascular complications and the progression of kidney disease that requires renal replacement therapy. Hypertension is a modifiable risk factor for cardiovascular complications and progression of CKD. 3 The recommendations outlined here are for the variety of clinicians who manage patients with diabetic kidney disease, including GPs and specialists in diabetes, cardiology and nephrology. They are intended to harmonise practices of blood pressure monitoring, and pharmacological and nonpharmacological management of hypertension, which may vary considerably.
Evidence grades for the recommendations
The following evidence grading has been used to determine the strength of the recommendations; the suggested audit standards; and the questions for areas that require future research.
1A -Strong recommendation: high-quality evidence 1B -Strong recommendation: moderate-quality evidence 1C -Strong recommendation: low-quality evidence 1D -Strong recommendation: very low-quality evidence 2A -Weak recommendation: high-quality evidence 2B -Weak recommendation: moderate-quality evidence 2C -Weak recommendation: low-quality evidence 2D -Weak recommendation: very low-quality evidence 1 Hypertension management and renin-angiotensin-aldosterone system blockade in patients with type 1 diabetes
Recommendations
The following are recommendations for renin-angiotensin-aldosterone system (RAAS) blockade and hypertension management in patients with type 1 diabetes.
1 In patients with type 1 diabetes and normoalbuminuria, we suggest a threshold for blood pressure therapy of a persistent upright (sitting or standing) blood pressure that is greater than or equal to 140/80 mmHg (Grade 2D).
In children and adolescents with type 1 diabetes, hypertension is defined as average systolic blood pressure and/or diastolic blood pressure that is greater than the 95th percentile for the patient's gender, age and height on more than three occasions (Grade 1B).
2 We recommend that angiotensin-converting-enzyme inhibitor (ACEI) therapy should be used as a first-line agent for blood pressure lowering and, if ACEI therapy is contraindicated or not tolerated, angiotensin receptor blockers (ARBs) should be considered (Grade 1B).
3 In most adults with type 1 diabetes and persistent microalbuminuria or macroalbuminuria, we recommend that ACEI therapy should be considered irrespective of blood pressure, and that the target upright blood pressure should be less than or equal to 130/80 mmHg. We recommend that the dose of ACEI should be titrated to the maximum tolerated (Grade 1B).
4 There is no current evidence to support a role for ACEI therapy for blood pressure control or renal protection in patients with type 1 diabetes who are normotensive and normoalbuminuric (Grade 1C).
5 There is some evidence to support the use of candesartan to prevent the development or progression of retinopathy in patients with type 1 diabetes who are normotensive and normoalbuminuric (Grade 1C).
6 There is no firm evidence to support a role of dual blockade of the RAAS in patients with type 1 diabetes (Grade 1C).
7 We recommend that women of childbearing age should be encouraged to stop RAAS-blocking drugs prior to actively considering pregnancy (Grade 1B).
8 We suggest that patients with type 1 diabetes with significant renal function impairment (eGFR <45 ml/min/1.73 m 2 ) should be advised to withhold RAAS-blocking drugs during periods of acute illness (not graded).
Audit standards
The following are suggested as audit standards for RAAS blockade and hypertension management in patients with type 1 diabetes.
3 The proportion of patients with type 1 diabetes and albuminuria who are on submaximal doses of ACEIs or ARBs due to hyperkalaemia or adverse reactions.
Areas that require further research
The following areas lack good-quality evidence for RAAS blockade and hypertension management in patients with type 1 diabetes, and hence further research is necessary.
1 In light of the fact that the presence of microalbuminuria in patients with type 1 diabetes may not be the best predictor of whether they will develop progressive renal disease, what is the role for other markers (such as kidney injury molecule-1 (KIM-1)) in predicting the risk of renal disease in patients with type 1 diabetes?
2 What is the role of dual RAAS blockade in patients with type 1 diabetes and nephropathy?
3 What is the role of aldosterone receptor blockers or direct renin inhibitors in patients with type 1 diabetes and nephropathy?
4 Is there a role for home or ambulatory blood pressure monitoring in the diagnosis and management of hypertension in patients with type 1 diabetes, particularly in those who have diabetic autonomic neuropathy?
5 Does measurement of plasma renin activity have a role in screening and managing hypertension in patients with type 1 diabetes?
6 Does tight glycaemic control and blood pressure lowering reduce the incidence of patients developing microvascular complications?
7 What is the role of RAAS-blocking agents in patients who have type 1 diabetes, progressive renal decline and normoalbuminuria?
Hypertension management and renin-angiotensin-aldosterone system blockade in patients with type diabetes, nephropathy and/or early chronic kidney disease (stages 1-3) Recommendations
The following are recommendations for RAAS blockade and hypertension management in patients with type 2 diabetes, nephropathy and/or early CKD.
7 There is currently no evidence to support the role of dual blockade of the RAAS in patients with type 2 diabetes and CKD stages 1 to 3 (Grade 1B).
8 Upright blood pressure targets should be set at no lower than 150/90 mmHg in those with type 2 diabetes who are aged 80 years or over (Grade 2B).
9 We suggest that patients with type 2 diabetes with significant renal function impairment (eGFR <45 ml/min/1.73 m 2 ) should be advised to withhold RAAS-blocking drugs during periods of acute illness (not graded).
Audit standards
The following are suggested as audit standards for RAAS blockade and hypertension management in patients with type 2 diabetes, early CKD and/or albuminuria.
1 The percentage of patients with type 2 diabetes who have CKD and urine AER of greater than 30 mg per 24 hours (ACR of greater than 3 mg/mmol) who are achieving the target upright blood pressure of less than 130/80 mmHg.
2 The proportion of patients with type 2 diabetes who have CKD and urine AER of greater than 30 mg per 24 hours (ACR of greater than 3 mg/mmol) who are on ACEIs or ARBs.
3 The percentage of patients with type 2 diabetes who have CKD and urine AER of greater than 30 mg per 24 hours (ACR of greater than 3 mg/mmol) who are not on ACEIs or ARBs (or who are on a suboptimal dosage) due to hyperkalaemia or a decrease in estimated glomerular filtration rate (eGFR) of greater than 25% or an increase in serum creatinine of greater than 30%.
4 The number of patients with type 2 diabetes and CKD who are on dual blockade of the RAAS.
Areas that require further research
The following areas lack good-quality evidence for RAAS blockade and hypertension management in patients with type 2 diabetes, nephropathy and/or early CKD, and hence further research is necessary.
1 What is the best method for blood pressure measurement in patients with type 2 diabetes who have CKD?
2 What is the evidence-based lower limit for blood pressure reduction in patients with type 2 diabetes who have CKD?
3 Does reduction in albuminuria with agents that do not modify blood pressure improve hard cardiovascular and renal outcomes?
4 Should RAAS inhibition be maximised in patients with CKD?
5 Can potassium binders enable a higher dosage of RAAS inhibitors with better attainment of blood pressure control and reduction in hyperkalaemia?
6 Is the use of mineralocorticoid antagonists beneficial in patients with type 2 diabetes and nephropathy?
7 What are the best second-and third-line blood pressure lowering agents in patients with type 2 diabetes who have CKD and albuminuria?
8 Is there a need for long-term outcome studies of non-dihydropyridine calcium channel blockers in diabetic nephropathy?
3 Hypertension management and renin-angiotensin-aldosterone system blockade in patients with type 2 diabetes, nephropathy and/or later stage chronic kidney disease -stages 4 and 5 (nondialysis)
Recommendations
The following are recommendations for the management of hypertension in patients with diabetes and chronic kidney disease (CKD) stages 4 and 5 (non-dialysis).
Hypertension management in patients with diabetes and chronic kidney disease who are on dialysis (stage 5D) Recommendations
The following are recommendations for blood pressure control in patients with diabetes and CKD stage 5D.
1 We recommend that ambulatory blood pressure measurement or home blood pressure measurement should be used to monitor blood pressure in patients with diabetes who are on dialysis (Grade 1C).
2 Where ambulatory blood pressure measurement or home measurement are not feasible to monitor blood pressure in patients with diabetes who are on dialysis, we suggest using pre-, intra-and post-dialysis blood pressure measurements for patients who are on haemodialysis, and using clinic blood pressure measurements for patients who are on peritoneal dialysis (Grade 2D).
3 We recommend volume control as a first-line management to optimise blood pressure control in patients with diabetes who are on dialysis (Grade 1B). 
